1. Home
  2. CMC vs PCVX Comparison

CMC vs PCVX Comparison

Compare CMC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commercial Metals Company

CMC

Commercial Metals Company

HOLD

Current Price

$69.12

Market Cap

7.5B

Sector

Industrials

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$56.51

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMC
PCVX
Founded
1915
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
7.0B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
CMC
PCVX
Price
$69.12
$56.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
4
Target Price
$73.33
$88.25
AVG Volume (30 Days)
1.2M
1.4M
Earning Date
03-26-2026
05-07-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
N/A
EPS
2.41
N/A
Revenue
$7,918,430,000.00
N/A
Revenue This Year
$18.81
N/A
Revenue Next Year
$6.34
N/A
P/E Ratio
$30.77
N/A
Revenue Growth
25.57
N/A
52 Week Low
$48.14
$29.10
52 Week High
$84.87
$65.00

Technical Indicators

Market Signals
Indicator
CMC
PCVX
Relative Strength Index (RSI) 40.00 60.67
Support Level $67.83 $52.04
Resistance Level $72.94 $56.04
Average True Range (ATR) 2.70 2.37
MACD -0.84 0.94
Stochastic Oscillator 8.15 74.71

Price Performance

Historical Comparison
CMC
PCVX

About CMC Commercial Metals Company

Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: